Preclinical evaluation of point-of-care prothrombin time as a biomarker test to guide prothrombin replacement therapy in coagulopathic bleeding.

Balendran, Clare A; Henderson, Neil; Olsson, Marita; Lövgren, Ann; Hansson, Kenny M

Balendran, Clare A; Henderson, Neil; Olsson, Marita; Lövgren, Ann; Hansson, Kenny M.

Afiliação

Balendran CA; Personalised Healthcare & Biomarkers Innovative Medicines and Early Biotech Unit AstraZeneca Mölndal Sweden.
Henderson N; Personalised Healthcare & Biomarkers Innovative Medicines and Early Biotech Unit AstraZeneca Mölndal Sweden.
Olsson M; Early Clinical Development, Innovative Medicines and Early Development Biotech Unit AstraZeneca Mölndal Sweden.
Lövgren A; Leaflet Biotech Consulting Solna Sweden.
Hansson KM; Cardiovascular and Metabolic Diseases Innovative Medicines and Early Development Biotech Unit AstraZeneca Mölndal Sweden.

Res Pract Thromb Haemost ; 1(2): 252-258, 2017 Oct.

Article em En | MEDLINE | ID: mdl-30046694

Palavras-chave

PT; biomarker; coagulopathy; pointofcare; prothrombin; severe bleeding

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google